BGI Genomics Co., Ltd.

SZSE:300676 Stock Report

Market Cap: CN¥15.1b

BGI Genomics Future Growth

Future criteria checks 3/6

BGI Genomics is forecast to grow earnings and revenue by 117.1% and 5.8% per annum respectively. EPS is expected to grow by 117.1% per annum. Return on equity is forecast to be 1% in 3 years.

Key information

117.1%

Earnings growth rate

117.14%

EPS growth rate

Biotechs earnings growth30.5%
Revenue growth rate5.8%
Future return on equity1.00%
Analyst coverage

Low

Last updated29 May 2026

Recent future growth updates

No updates

Recent updates

Analysis Article • Feb 07

BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 26%

BGI Genomics Co., Ltd. ( SZSE:300676 ) shareholders are no doubt pleased to see that the share price has bounced 26% in...
Analysis Article • Jan 21

Does BGI Genomics (SZSE:300676) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Oct 22

Is BGI Genomics (SZSE:300676) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article • Oct 01

BGI Genomics Co., Ltd. (SZSE:300676) Held Back By Insufficient Growth Even After Shares Climb 31%

The BGI Genomics Co., Ltd. ( SZSE:300676 ) share price has done very well over the last month, posting an excellent...
Analysis Article • Jul 15

Is BGI Genomics (SZSE:300676) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 22

Why Investors Shouldn't Be Surprised By BGI Genomics Co., Ltd.'s (SZSE:300676) Low P/S

BGI Genomics Co., Ltd.'s ( SZSE:300676 ) price-to-sales (or "P/S") ratio of 3.6x might make it look like a strong buy...
Analysis Article • Apr 21

BGI Genomics' (SZSE:300676) Conservative Accounting Might Explain Soft Earnings

Soft earnings didn't appear to concern BGI Genomics Co., Ltd.'s ( SZSE:300676 ) shareholders over the last week. We did...
Analysis Article • Mar 25

Here's Why BGI Genomics (SZSE:300676) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Earnings and Revenue Growth Forecasts

SZSE:300676 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20284,476140N/A8061
12/31/20274,13067N/A7401
12/31/20263,885-1N/A6891
3/31/20263,842-573-356153N/A
12/31/20253,705-617-569-63N/A
9/30/20253,715-800-639-198N/A
6/30/20253,627-915-823-238N/A
3/31/20253,718-968-816-225N/A
12/31/20243,867-903-43496N/A
9/30/20244,032-102-57184N/A
6/30/20244,14961-584326N/A
3/31/20244,21664-794311N/A
12/31/20234,35093-828409N/A
9/30/20235,679126-1,189504N/A
6/30/20235,964247-1,179358N/A
3/31/20236,578514-569827N/A
1/1/20237,053803-1,136131N/A
9/30/20226,132794-144530N/A
6/30/20226,2819811,0861,586N/A
3/31/20226,6331,2671,2051,670N/A
1/1/20226,7661,4622,0932,476N/A
9/30/20216,7977982,4382,759N/A
6/30/20217,9361,5231,8812,229N/A
3/31/20219,1692,4743,2553,545N/A
12/31/20208,3972,0893,3023,603N/A
9/30/20207,4802,7122,6022,970N/A
6/30/20205,6171,7301,9822,385N/A
3/31/20203,00931883712N/A
12/31/20192,800276N/A224N/A
9/30/20192,795337N/A14N/A
6/30/20192,687377N/A-38N/A
3/31/20192,603384N/A-131N/A
12/31/20182,536387N/A15N/A
9/30/20182,463406N/A18N/A
6/30/20182,348415N/A138N/A
3/31/20182,224404N/A150N/A
12/31/20172,096398N/A244N/A
9/30/20171,901388N/A145N/A
6/30/20171,833375N/A203N/A
3/31/20171,796352N/AN/AN/A
12/31/20161,711333N/A234N/A
6/30/20161,520336N/A296N/A
3/31/20161,339299N/AN/AN/A
12/31/20151,319262N/A329N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300676 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: 300676 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 300676 is expected to become profitable in the next 3 years.

Revenue vs Market: 300676's revenue (5.8% per year) is forecast to grow slower than the CN market (16.1% per year).

High Growth Revenue: 300676's revenue (5.8% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300676's Return on Equity is forecast to be low in 3 years time (1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/05 17:28
End of Day Share Price 2026/08/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BGI Genomics Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wen DaiHuatai Research
Jiaxi XuIndustrial Securities Co. Ltd.
Yuan Yuan SunIndustrial Securities Co. Ltd.